IOVA - Iovance Biotherapeutics Inc logo

IOVA

Iovance Biotherapeutics Inc

Rev โ€”top 1%10Y
Hold

Iovance Biotherapeutics develops and commercializes cell therapies using tumor infiltrating lymphocytes to treat metastatic melanoma and other solid tumors. Its products include Amtagvi and Proleukin, targeting various cancers through innovative therapies.

โš•๏ธ Healthcare NASDAQ Listed 2010 $ USD
$1,000 invested 10 years ago โ†’$720today

Score Overview

1 Year
Score
Net Growth25.95%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growth23.33%
Rev TrendGrew
Revenue Consistencyโ€”
5 Years
Scoreโ€”
Net Growth11.68%
Net Trend40%
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendEvery year
Revenue Consistencyโ€”
10 Years
Scoreโ€”
Net Growth-447.35%
Net Trend20%
Net Income Consistency
Rev Growthโ€”
Rev Trend50%
Revenue Consistency
All Time
Scoreโ€”
Net Growth-178x
Net Trend25%
Net Income Consistency
Rev Growthโ€”
Rev Trend33%
Revenue Consistency

See the full market ranking โ†’

Iovance Biotherapeutics Inc fundamental performance

Across Iovance Biotherapeutics Inc's full reported history, from 2010 to 2025, net income went from -$ 1M to -$ 390M. Revenue increased in 33% of the years measured; net income in 25%.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-13
$ 6.52โ€”
1 Year2025-08-13
$ 2.45166.12%
5 Years2021-08-13
$ 21.77-70.05%
10 Years2016-08-12
$ 9.05-27.96%
All Time2010-10-15
$ 110.00-94.07%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 324M-$ 289M$ 297M
2025$ 263M-$ 390M$ 296M
2024$ 164M-$ 372M$ 323M
2023$ 1M-$ 444M$ 279M
2022$ 238K-$ 389M$ 471M
2021$ 0.00-$ 327M$ 504M
2020$ 0.00-$ 259M$ 629M
2019$ 0.00-$ 187M$ 307M
2018$ 0.00-$ 123M$ 468M
2017$ 0.00-$ 92M$ 145M
2016$ 0.00-$ 52M$ 166M
2015$ 0.00-$ 27M$ 103M
2014$ 0.00-$ 12M$ 44M
2013$ 0.00-$ 25M$ 19M
2012$ 0.00-$ 3M
2011$ 0.00-$ 25M$ 519.61K
IPO2010-$ 1M$ 1M

Explore beyond IOVA

You're looking at Iovance Biotherapeutics Inc. Members apply the same fundamental framework across all 3,859 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies